Welcome to our dedicated page for Vigil Neuroscience SEC filings (Ticker: VIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vigil Neuroscience filings document the company’s public-company status, capital structure, governance and biotechnology disclosure record. Recent corporate-status filings include a Form 25 covering removal of its common stock from Nasdaq listing and registration under Section 12(b), and a Form 15 covering termination of Section 12(g) registration or suspension of Exchange Act reporting duties, with one holder of record identified in the certification.
The company’s 8-K disclosures cover material events, material agreements, shareholder voting matters, capital-structure items, governance matters, clinical or regulatory disclosures, and operating and financial results tied to its microglia-focused neurodegenerative disease programs.
Vigil Neuroscience, Inc. Schedule 13G/A filed by a group of related entities led by Biotechnology Value Fund and Mark N. Lampert reports that, as of the close of business on June 30, 2025, the Reporting Persons no longer beneficially owned any shares of Vigil Neuroscience common stock (CUSIP 92673K108). The filing lists each reporting entity, their jurisdictions (mostly Delaware, some Cayman Islands), the reporting address for BVF entities, and confirms zero sole or shared voting and dispositive power for all listed persons. The statement is signed by Mark N. Lampert on behalf of the reporting entities on August 14, 2025.
Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 3,012,068 shares of Vigil Neuroscience common stock, representing 6.45% of the class as of the reporting event date 06/30/2025. The filing indicates the Reporting Persons have shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The statement identifies Glazer Capital as an investment manager and Mr. Glazer as its managing member and includes the issuer's principal office in Watertown, MA. The Reporting Persons certify the shares were not acquired to change or influence control of the issuer. The filing is signed 08/14/2025.
Vigil Neuroscience, Inc. (VIGL) submitted Post-Effective Amendments to four outstanding Form S-8 registration statements after completing its 5 Aug 2025 merger with Sanofi. The merger converted Vigil into a wholly owned Sanofi subsidiary, triggering automatic termination of all employee-equity offerings covered by the S-8s.
The amendments deregister every share that remained unissued under the company’s: (1) Amended & Restated 2020 Equity Incentive Plan, (2) 2021 Stock Option & Incentive Plan, (3) 2021 Employee Stock Purchase Plan, and (4) a 330,000-share inducement option. The four S-8s had originally registered a combined 12 million+ common shares between 2022 and 2025. By filing the amendments, Vigil formally removes those unsold shares from SEC registration, eliminating potential dilution and closing out the plans. No financial metrics, earnings data or forward-looking statements are included in the filing.
Vigil Neuroscience (VIGL) – Form 4 (08/05/25): Director Mary Thistle reports the disposition of 5,000 common shares and the cash-out of 68,460 in-the-money stock options/RSUs at the closing of Vigil’s merger with Sanofi.
At the Effective Time (5 Aug 2025), Sanofi’s Vesper Acquisition Sub merged into Vigil, making Vigil a wholly owned subsidiary. Each Vigil share outstanding was converted into (i) $8.00 cash and (ii) one contingent value right (CVR) worth up to $2.00 subject to a clinical milestone. All unvested RSUs and stock options vested immediately; options with a strike below $8.00 were cancelled for a cash payment equal to the intrinsic value plus one CVR per underlying share.
Following the conversion, Thistle holds no remaining equity in Vigil. The filing confirms consummation of the merger and the final equity treatment for insiders and, by extension, public shareholders.